Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus lenvatinib in refractory advanced colorectal cancer (Phase I/II)
KCT0012000Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of capecitabine and lenvatinib in colorectal cancer (CRC), colon cancer, rectal cancer and 1 more, sponsored by Boryung. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
capecitabinelenvatinib
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancerrectosigmoid cancer
Beyond the preview
Go deeper on KCT0012000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012000.